Across TCGA pan-cancer cohorts, TCEAL2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of TCEAL2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TCEAL2 RNA is repressed in tumor relative to normal tissue. In most cancer types TCEAL2 is over-expressed in tumor, although a few such as KIRC and BLCA show the opposite, repressed pattern.

KIRC, BLCA, and KICH are the cancer types where TCEAL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCEAL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	−3.895	<.001	12	view →
BLCA	Male	IV	−4.405	<.001	11	view →
KICH	Male	III,IV	−3.910	<.001	11	view →
KIRP	Male	II,III,IV	−3.756	<.001	11	view →
LUAD	Male	III,IV	−2.976	<.001	11	view →
COAD	Male	II,III,IV	−2.595	<.001	11	view →
HNSC	Male	All	−1.296	<.001	11	view →
THCA	Male	IV	−6.123	<.001	10	view →
LUSC	Male	III,IV	−3.215	<.001	8	view →
STAD	Female	All	−3.570	<.001	7	view →
UCEC	All	All	−3.694	<.001	6	view →
BRCA	Female	All	−1.807	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

Exploration

Same gene, other analysis: TCEAL2 RNA expression & survival · all TCEAL2 data types